Cogent Biosciences Q2 2026 Earnings Report

Cogent Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.55
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cogent Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.00 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cogent Biosciences Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 5, 2026
• Conference Call Time: 12:30PM ET

Cogent Biosciences (NASDAQ:COGT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development.

Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs.